Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Cost-effectiveness of antiretroviral therapy expansion strategies in Vietnam.

Tran DA, Wilson DP, Shakeshaft A, Ngo AD, Reyes J, Doran C, Zhang L.

AIDS Patient Care STDS. 2014 Jul;28(7):365-71. doi: 10.1089/apc.2014.0016.

PMID:
24983389
[PubMed - indexed for MEDLINE]
2.

Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.

AIDS. 2007 Jul;21 Suppl 4:S117-28.

PMID:
17620747
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study.

Badri M, Cleary S, Maartens G, Pitt J, Bekker LG, Orrell C, Wood R.

Antivir Ther. 2006;11(1):63-72.

PMID:
16518961
[PubMed - indexed for MEDLINE]
4.

Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa.

Alistar SS, Grant PM, Bendavid E.

BMC Med. 2014 Mar 17;12:46. doi: 10.1186/1741-7015-12-46.

PMID:
24629217
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

When to start antiretroviral therapy in resource-limited settings.

Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, Martinson NA, Paltiel AD, Anglaret X, Weinstein MC, Losina E; CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators.

Ann Intern Med. 2009 Aug 4;151(3):157-66. Epub 2009 Jul 20.

PMID:
19620143
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:147-67. doi: 10.2165/11587500-000000000-00000.

PMID:
21182349
[PubMed - indexed for MEDLINE]
7.

Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.

Mauskopf J, Brogan A, Martin S, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000.

PMID:
21182346
[PubMed - indexed for MEDLINE]
8.

Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients.

Kimmel AD, Goldie SJ, Walensky RP, Losina E, Weinstein MC, Paltiel AD, Zhang H, Freedberg KA; Cost-Effectiveness of Preventing AIDS Complications Investigators.

Antivir Ther. 2005;10(1):41-52.

PMID:
15751762
[PubMed - indexed for MEDLINE]
9.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

PMID:
25104632
[PubMed - in process]
Free Article
10.

US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.

Brogan A, Mauskopf J, Talbird SE, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:129-46. doi: 10.2165/11587490-000000000-00000.

PMID:
21182348
[PubMed - indexed for MEDLINE]
11.

Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe.

Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugyenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team.

PLoS One. 2012;7(4):e33672. doi: 10.1371/journal.pone.0033672. Epub 2012 Apr 24.

PMID:
22545079
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.

Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):91-100.

PMID:
17621241
[PubMed - indexed for MEDLINE]
13.

How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa?

Scott Braithwaite R, Nucifora KA, Toohey C, Kessler J, Uhler LM, Mentor SM, Keebler D, Hallett T.

AIDS. 2014 Jan;28 Suppl 1:S73-83. doi: 10.1097/QAD.0000000000000110.

PMID:
24468949
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.

Moeremans K, Annemans L, Löthgren M, Allegri G, Wyffels V, Hemmet L, Caekelbergh K, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:107-28. doi: 10.2165/11587480-000000000-00000.

PMID:
21182347
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.

Brogan AJ, Talbird SE, Cohen C.

Value Health. 2011 Jul-Aug;14(5):657-64. doi: 10.1016/j.jval.2011.01.009. Epub 2011 Jun 12.

PMID:
21839403
[PubMed - indexed for MEDLINE]
16.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group.

Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18.

PMID:
23602084
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.

Moreno S, González J, Lekander I, Martí B, Oyagüez I, Sánchez-de la Rosa R, Casado MA.

Clin Ther. 2010 Dec;32(13):2232-45. doi: 10.1016/S0149-2918(10)80026-8.

PMID:
21316539
[PubMed - indexed for MEDLINE]
18.

Economic evaluation of ART in resource-limited countries.

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y.

Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d. Review.

PMID:
20539078
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164.

Sax PE, Sloan CE, Schackman BR, Grant PM, Rong J, Zolopa AR, Powderly W, Losina E, Freedberg KA; Cepac US And Actg A5164 Investigators.

HIV Clin Trials. 2010 Sep-Oct;11(5):248-59. doi: 10.1310/hct1105-248.

PMID:
21126955
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.

Hill AM, Gebo K, Hemmett L, Löthgren M, Allegri G, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:169-81. doi: 10.2165/11587510-000000000-00000.

PMID:
21182350
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk